Results 121 to 130 of about 1,063 (182)

Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide. [PDF]

J Comp Eff Res
Lowentritt BH, Burbage S, Khilfeh I, Pilon D, Du S, Rossi C, Kinkead F, Diaz L, Brown G.   +8 more
europepmc   +1 more source

Cutaneous Adverse Reactions to Apalutamide: Case Series with Clinical and Pathological Correlations. [PDF]

Acta Derm Venereol
Gil-Lianes J, Amat-Samaranch V, Giavedoni P, Vilaseca A, Córdoba Sánchez J, Alamon-Reig F, Castillo P, Garcia AP, Pascal M, Carrera C.   +9 more
europepmc   +1 more source

Severe cutaneous adverse reactions associated with second-generation androgen receptor antagonists in prostate cancer patients. [PDF]

PLoS One
Liu J, Liu X, Zeng H, Tong Y, Chen Z, Dong Z.   +5 more
europepmc   +1 more source

Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. [PDF]

Cancer Med
Miura H, Yamamoto H, Okuyama Y, Ishi N, Tanaka R, Oishi T, Yoneyama F, Hamaya T, Togashi K, Fujita N, Okamoto T, Ohyama C, Hatakeyama S.   +12 more
europepmc   +1 more source

Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs. [PDF]

Future Oncol
Yu EY, Gratzke C, Burotto M, Zhang AY, Lévesque E, Ortega F, Peer A, Vile D, Chen ZH, Song Y, Schloss C, Todoric J, Garratt C, Poehlein C, Antonarakis ES, Fizazi K.   +15 more
europepmc   +1 more source

Dermatological adverse events in Chinese prostate cancer patients treated with the androgen receptor inhibitor apalutamide. [PDF]

Front Immunol
Wang Q, Ren ZT, Wu HF, Gu HC, Li XW, Tang ZL.   +5 more
europepmc   +1 more source

Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC. [PDF]

Jpn J Clin Oncol
Tohi Y, Kobayashi K, Daizumoto K, Sekino Y, Fukuhara H, Niigawa H, Katayama S, Shimizu R, Takamoto A, Nishimura K, Nagami T, Hayashida Y, Hirama H, Shiraishi K, Tomida R, Kobatake K, Inoue K, Miyaji Y, Bekku K, Morizane S, Miura N, Wada K, Sugimoto M, Chu-shikoku Japan Urological Consortium .   +23 more
europepmc   +1 more source

Pharmacist Intervention in Outpatients With Prostate Cancer Prevents Apalutamide-induced Skin Adverse Events. [PDF]

In Vivo
Umehara K, Saito Y, Takada S, Yamagishi K, Takada N, Maruyama S, Harabayashi T, Hashishita H.   +7 more
europepmc   +1 more source

Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. [PDF]

Int J Clin Pharm
Pons-Fuster E, Gonzalez-Ponce CM, Ros-Martinez S, Fernández-Ávila JJ, Díaz-Carrasco MS, Espuny-Miró A.   +5 more
europepmc   +1 more source

Systemic treatment of metastatic castration-sensitive prostate cancer: A meta-analysis of efficacy and safety. [PDF]

Medicine (Baltimore)
Zhang M, Wan L, Yao Y, Wu R, Li W, Gu P.
europepmc   +1 more source